Celgene
NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing Price on November 22, 2019
CELG Articles
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Celgene released better-than-expected quarterly results and updated guidance before the markets opened on Thursday.
Published:
Last Updated:
The July 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly, Gilead Sciences and some of the other, larger health care companies that are about to report their quarterly results.
Published:
Last Updated:
Acceleron Pharma shares dipped on Friday after the company provided an update on an orphan drug designation from the FDA.
Published:
Last Updated:
The June 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Acceleron Pharma and Celgene each saw a handy gain on Tuesday morning after it was announced results from their late-stage study in adults with transfusion-dependent beta-thalassemia.
Published:
Last Updated:
A few biopharma stocks made massive runs over the course of this past week, some losing more than half their cap. Not all these moves were negative, but the overall sentiment was negative.
Published:
Last Updated:
Acceleron Pharma and Celgene each saw gains on Friday after they reported results from a late-stage trial.
Published:
Last Updated:
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest moves...
Published:
Last Updated:
The two most-shorted Nasdaq stocks held onto their positions in the short-interest reporting period that ended on May 31. There was one big mover in an otherwise mostly calm two weeks.
Published:
Last Updated:
It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the top companies are starting to apply...
Published:
Last Updated:
The May 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Celgene, Cypress Semiconductor, Intuit, KemPharm, Oasis Petroleum, Rio Tinto and Shake Shack.
Published:
Last Updated: